Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This case report describes an 82-year-old female patient with myasthenia gravis (MG) who presented with worsening dysphagia. The patient was found to have cricopharyngeal sphincter and esophageal achalasia, and a percutaneous endoscopic gastrostomy (PEG) tube was placed due to severe pharyngeal dysphagia and cricopharyngeal dysfunction. The patient had class IVb myasthenia gravis and was treated with intravenous immunoglobulin (IVIG), prednisone, and pyridostigmine. The report discusses the link between myasthenia gravis and dysphagia, which is seen in 20% of patients. The report also explores the relationship between myasthenia gravis and achalasia, which is a rare disorder characterized by the failure of relaxation of the sphincter muscles. While myasthenia gravis leads to muscle weakness and should not cause achalasia, there have been a few case reports describing a link between the two disorders. Cricopharyngeal dysfunction, which is a common disorder causing dysphagia in the elderly, was also noted in the patient. The report highlights that cricopharyngeal dysfunction may be primary or secondary, with the latter often being associated with inflammatory myopathies such as polymyositis or mixed connective tissue disorders. The patient did not have a workup for other autoimmune diseases that could have been the cause of achalasia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460275PMC
http://dx.doi.org/10.7759/cureus.42575DOI Listing

Publication Analysis

Top Keywords

myasthenia gravis
24
cricopharyngeal dysfunction
12
cricopharyngeal sphincter
8
dysfunction patient
8
patient myasthenia
8
case report
8
patient
6
myasthenia
6
gravis
6
achalasia
5

Similar Publications

Myasthenia gravis (MG) presents significant health and economic challenges. To identify novel biomarkers, we analyzed proteomic data from 52,704 UK Biobank individuals, focusing on 1463 baseline proteins with follow-up >10 years. Baseline and potential MG cases were 1:5 matched to controls by using propensity score matching.

View Article and Find Full Text PDF

We report the management of a 64-year-old male with newly diagnosed bulbar-onset myasthenia gravis (MG) who was hospitalized with acute neuromuscular respiratory insufficiency. This case highlights the challenges in monitoring respiratory function in MG patients, especially in the presence of bulbar and nuchal weakness, and emphasizes the potential utility of single breath-hold time (SBHT) over forced vital capacity (FVC) as a reliable bedside monitoring tool. Despite initial stabilization with intravenous immunoglobulin (IVIG), the patient deteriorated, requiring escalation to the intensive care unit (ICU), and the clinical worsening corresponded with the SBHT rather than with FVC.

View Article and Find Full Text PDF

CD19CD11cT-bet B cells in myasthenia gravis: a potential biomarker.

Front Neurol

August 2025

Department of Neurology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.

Background: Myasthenia gravis (MG), an autoimmune disorder characterized by B cell-driven autoantibody production, exhibits heterogeneous B cell subsets dysregulation and incompletely defined signaling mechanisms.

Methods: A cohort of 20 naïve MG patients positive for anti-acetylcholine receptor (AChR) antibodies and 15 healthy controls was analyzed. Peripheral blood mononuclear cells underwent proteomic profiling, flow cytometry (age-associated B cells (ABCs), plasma cells, T follicular helper cells, and regulatory B cells), and western blot validation of nuclear factor kappa-B (NF-κB)/cellular reticuloendotheliosis oncogene homolog (c-Rel) expression.

View Article and Find Full Text PDF

We present a clinically instructive case of a 50-year-old woman with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG) who subsequently developed glutamic acid decarboxylase 65 (GAD65) antibody-associated neurological disorders alongside a type B2 thymoma. This rare coexistence highlights the profound immune dysregulation induced by thymomas, wherein loss of self-tolerance emergence multiple concurrent autoimmune phenomena. The patient's favorable response to multimodal immunotherapy-including efgartigimod, high-dose corticosteroids, and rituximab-underscores the therapeutic imperative for early, targeted immunomodulation in such complex neuroimmunological syndromes.

View Article and Find Full Text PDF

Early intervention in impending myasthenic crisis (IMC) is critical to avert life-threatening progression. This study compared the clinical effectiveness and safety of the novel FcRn antagonist efgartigimod versus intravenous immunoglobulin (IVIg) in IMC management. In this retrospective cohort study, we analyzed 51 acetylcholine receptor antibody-positive (AChR-Ab+) IMC patients who received either efgartigimod (n ​= ​30) or IVIg (n ​= ​21) from June 2023 to November 2024.

View Article and Find Full Text PDF